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OBJECTIVES Our aim was to examine the rate of adverse cardiac events in patients undergoing magnetic
resonance imaging (MRI) 8 weeks after coronary stent placement.
BACKGROUND The risk of coronary stent thrombosis from dislodgement due to MRI early after stent
placement is not well defined. Manufacturers recommend postponing MRI studies until eight
weeks after coronary stent placement.
METHODS We analyzed the Mayo Clinic Rochester Percutaneous Coronary Intervention Database and
examined records of 111 patients who underwent MRI 8 weeks after coronary stent
placement treated with aspirin and a thienopyridine. Occurrence of death, myocardial
infarction (MI), and repeat revascularization within 30 days of MRI were recorded.
RESULTS Magnetic resonance imaging (1.5 tesla) was performed within a median of 18 days (range, 0
to 54 days) after coronary stent placement. Four noncardiac deaths occurred, and three
patients had repeat revascularization procedures. Stent thrombosis did not occur (95%
confidence interval, 0% to 3.3%).
CONCLUSIONS Magnetic resonance imaging8 weeks after coronary stent placement appears to be safe, and
the risk of cardiac death or MI due to stent thrombosis is low. Postponing MRI does not
appear to be necessary. (J Am Coll Cardiol 2003;42:1295–8) © 2003 by the American
College of Cardiology Foundation
Magnetic resonance imaging (MRI) is considered unsafe in
the presence of many metallic cardiovascular devices because
it may cause dislodgement of the device by ferromagnetic
force, device heating, flow of electrical currents, or malfunc-
tion of a device’s electrical system (1–3). Every year approx-
imately 457,000 metallic coronary artery stents (CASs) are
placed (4). In patients with CASs, MRI is believed to be
safe once endothelialization (5) has occurred, because en-
dothelialization presumably opposes possible dislodgement
(3). Therefore, manufacturers of CASs (6,7) and profes-
sional associations of cardiologists (8) recommend postpon-
ing elective MRI examinations for four to eight weeks after
stent placement.
However, the need for urgent or emergent MRI can arise
within this period. Opinions differ about whether it is safe
to perform MRI8 weeks after CAS placement (9,10), and
physicians may choose to avoid MRI because of safety
concerns. Dislodgement could theoretically increase the
exposure of metallic coronary stent material to platelets,
which may trigger stent thrombosis, resulting in cardiac
death, myocardial infarction (MI), or emergent revascular-
ization. In vitro and animal studies (11–14) have shown that
ferromagneticity and stent migration are absent or minimal
with MRI of currently available stents. However, very few
clinical data are available on the outcome of patients who
undergo MRI early after CAS placement (15,16).
In addition to their clinical importance, data on the safety
of MRI early after CAS placement are also needed for
designing clinical studies that use MRI (e.g., to compare the
efficacy of different treatment modes for acute MI or to
assess the status of CASs) (16–18). Therefore, we retro-
spectively examined the rates of adverse cardiac events
occurring within 30 days after MRI performed 8 weeks
after placement of a CAS.
METHODS
Patients. We analyzed the Mayo Clinic Rochester Percu-
taneous Coronary Intervention Database, which contains
demographic, clinical, angiographic, and procedural data.
Immediate and in-hospital events are recorded, and all
patients are contacted for follow-up at six and 12 months
and yearly thereafter. For the present analysis, we identified
all patients who had CAS placement between July 1, 1994,
and November 30, 2001. After CAS placement, all patients
had received a thienopyridine for no longer than four weeks
in addition to aspirin. By cross-referencing the archive
system of the Mayo Clinic Department of Radiology, we
identified all patients who had undergone an MRI exami-
nation 8 weeks after CAS placement. If more than one
CAS placement preceded MRI, the time interval to MRI
was counted from the latest CAS placement.
The study was approved by the Mayo Foundation Insti-
tutional Review Board. Patients who denied access to their
medical record for research purposes (n 4) were excluded.
Outcomes. We queried the database for the occurrence of
death from any cause, MI, or repeat revascularization
procedures within 30 days after the MRI examination. If
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more than one MRI was performed 8 weeks after CAS
placement, the follow-up period was extended to 30 days
from the latest MRI. An investigator reviewed medical
records to establish the nature of clinical events recorded in
the database. For patients who died, clinical data and
autopsy reports were reviewed, and death was classified as
cardiac or noncardiac. For repeat percutaneous coronary
interventions, catheterization reports and films were
reviewed.
An MI was diagnosed if any two of the following three
criteria were met: 1) “typical” chest pain that lasted 20
min; 2) an elevation of creatine kinase or of its MB
isoenzyme 2 times the upper limit of normal; or 3) new
Q-waves or ST-T segment changes suggestive of MI on an
electrocardiogram.
Stent thrombosis was considered to have occurred if at
least one of the following was present: 1) confirmation on
autopsy or by coronary angiography; 2) MI in the territory
of the treated vessel without definite exclusion of stent
thrombosis; 3) sudden death without a clear noncardiac
cause.
Statistical analysis. Data are presented as mean  SD,
median, or percentages. Exact binomial confidence intervals
were calculated.
RESULTS
Of 112 patients who underwent CAS placement followed
by MRI within eight weeks and were eligible for the study,
one was lost to follow-up. The remaining 111 (mean age, 67
 12 years) had a median of two stents placed (range, one
to six). Comorbid conditions and angiographic and proce-
dural characteristics are shown in Table 1.
All MRI examinations were performed on one of two
types of 1.5-tesla MRI units (Signa, General Electric
Medical Systems, Waukesha, Wisconsin, or Gyroscan,
Philips Medical Systems, Best, The Netherlands). During
the eight weeks after CAS placement, 128 MRI examina-
tions were performed. The following body parts were
imaged: head or neck, 50 (39%); spine, 27 (21%); abdomen
or pelvis, 18 (14%); extremities, 13 (10%); chest, 11 (9%);
and combined examination of several body parts, 9 (7%).
Fifteen patients had1 MRIs (13 patients had 2; 2 patients
had 3).
The mean time interval from CAS placement to MRI
was 21  17 days (median, 18; range, 0 to 54 days).
Magnetic resonance imaging was performed within two
days after CAS placement in 15 patients (14%) and within
14 days in 52 patients (47%).
Stent thrombosis as defined by the study criteria did not
occur. The 95% exact confidence interval for no events in
111 patients is 0% to 3.3%. Seven clinical events occurred in
six (5%) of the 111 patients during the 30 days after MRI
(Table 2), including four noncardiac deaths and three repeat
revascularization procedures (all percutaneous coronary in-
terventions).
DISCUSSION
This study shows that the risk of cardiac death, MI, or need
for repeat revascularization due to stent thrombosis associ-
ated with MRI performed 8 weeks after CAS placement
is very low. The results are consistent with the 30-day
cardiac event rates (0.5% to 1.9%) after CAS placement
with contemporary antiplatelet therapy in patients not
undergoing MRI (19).
MRI after coronary stent placement. In a series of 13
patients who underwent MRI 3  1 days after CAS
placement for MI, no early adverse cardiac events occurred
in the postinfarct period (16). In other small observational
studies with longer intervals from elective CAS placement
to MRI, stent thrombosis was also rare (15,17).
Our study includes the largest series to date of patients
who underwent MRI before CASs could be fully endothe-
lialized (5). For all MRIs, the heart was at or near the
isocenter of the magnet, and therefore, the CAS were
exposed to the scanners’ full magnetic field strength and
spatial gradient. Our patients underwent MRI early after
CAS placement, contrary to conventional clinical practice,
Abbreviations and Acronyms
CAS(s)  coronary artery stent(s)
MI  myocardial infarction
MRI  magnetic resonance imaging
Table 1. Baseline Clinical and Procedural Characteristics of the




Prior MI 60 (54)
Prior PTCA 30 (27)
Prior CABG 20 (18)
Prior CVA/TIA 25 (23)
Diabetes 38 (34)
Current/former smoker 75 (68)
Moderate/severe renal disease† 12 (11)
Cancer 3 (3)
Acute coronary syndrome 59 (53)
CHF on presentation 14 (13)
Preprocedural shock 3 (3)
No. of coronary arteries with significant stenoses
2 41 (37)
3 43 (39)
Type B2 or C lesion (20) 89 (80)
Thrombus in any lesion 30 (27)
Summed length of stents used, mm 22  15
3 Stents placed 16 (14)
Average stent size, mm 3.3  0.6
Stent diameter 3 mm 17 (15)
*Categorical variables are expressed as number (percentage) and continuous variables
as mean  SD; †Creatinine 265 mol/l, current dialysis, or history of kidney
transplant.
CABG  coronary artery bypass graft; CHF  congestive heart failure; CVA 
cerebrovascular accident; MI  myocardial infarction; PTCA  percutaneous
transluminal coronary angioplasty; TIA  transient ischemic attack.
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because of severe comorbidity (Table 1). Accordingly, all
deaths during the follow-up period resulted from with-
drawal of respiratory support or from stroke (Table 2).
The prevalence in our study group of factors known to be
associated with increased risk of stent thrombosis (19,20)
(Table 1) suggests that our patients were at least at inter-
mediate risk of adverse cardiac events. Therefore, the
absence of CAS thrombosis in our study cannot be attrib-
uted to selection bias toward patients with low procedural
risk. The three repeat percutaneous coronary interventions
were performed remote from the original treatment sites (n
 2) or for in-stent restenosis (n  1), which was easily
distinguished from stent thrombosis by its far less acute
course (21).
Study limitations. Without complete 30-day angiographic
follow-up, we cannot exclude the possibility that the pres-
ence of subclinical stent thrombosis was not detected in
some patients with concurrent, critical illness. However,
subclinical stent thrombosis is believed to be a very rare
occurrence, and the close observation of this patient group
warranted by their comorbid conditions may actually have
resulted in higher than normal sensitivity for detecting
cardiac events.
Despite the large number of patients in this series, the
confidence intervals remain wide, and a stent thrombosis
rate as high as 3.3% cannot be excluded with certainty. In
addition, the MRI field strength in our study was limited to
1.5 T. Thus, it may not be appropriate to extrapolate from
our data to newer, higher field strength MRI scanners.
Nevertheless, our data suggest that MRI with field
strengths up to 1.5 T can be performed safely 8 weeks
after CAS placement. Current clinical practice and recom-
mendations by manufacturers of CASs to postpone MRI
studies until after eight weeks from CAS placement do not
seem necessary.
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